康柏西普对糖尿病视网膜病变患者血清中VEGF与IGF-1的影响研究

目的 观察康柏西普对糖尿病视网膜病变患者的治疗效果及其对血清中血管内皮生长因子(VEGF)和胰岛素样生长因子1(IGF-1)水平的影响.方法 选取2014年5月至2016年5月我院收治的糖尿病视网膜病变患者86例(86眼),将所有患者随机分为对照组与观察组,每组患者各43例,对照组患者采取一次性玻璃体腔中注射药物曲安奈德0.1mL,观察组患者采取一次性玻璃体腔中注射药物康柏西普0.05mL.采取酶联免疫吸附法(ELISA)测定治疗前及治疗后1个月、3个月两组患者血清中VEGF与IGF-1的水平,评价两组患者治疗3个月后的临床疗效以及调查患者生活质量,记录治疗后1个月不良反应情况.结果 对照组与观察组患者在药物治疗前后血清中VEGF与IGF-1的水平差异有统计学意义;两两比较的结果显示,与治疗前相比,对照组与观察组治疗后1个月和3个月患者血清中的VEGF和IGF-1水平较治疗前均降低,差异有统计学意义;对照组与观察组治疗后3个月患者血清中的VEGF和IGF-1水平均低于治疗后1个月,差异有统计学意义.同一时间点,观察组与对照组的比较结果显示,治疗后1个月和治疗后3个月观察组患者血清中VEGF与IFG-1水平均低于对照组,差异有统计学意义;观察组患者治疗后的总有效率为95%高于对照组(79%);治疗3个月后观察组患者自理能力、活动能力、社交和心理能力方面评分均高于对照组(P<0.05);治疗1个月后观察组患者前房炎性反应、角膜水肿和高眼压的发生率均明显低于对照组(P<0.05).结论 康柏西普能够明显降低糖尿病视网膜病变患者血清中VEGF与IGF-1的水平,延缓血管的生成,提高患者的生活质量,具有很好的临床疗效和安全性.

Effect of Composin on Serum VEGF and IGF-1 in Patients with Diabetic Retinopathy

Objective To observe the therapeutic effect of Composin on patients with diabetic retinopathy and its effect on serum levels of vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1).Methods 86 patients (86 eyes) with diabetic retinopathy treated in our hospital from May 2014 to May 2016 were randomly divided into control group and observation group.There were 43 patients in each group and control group took a one-time intravitreal injection of triamcinolone acetonide 0.1mL, the observation group of patients took a one-time vitreous cavity injection of drugs Composin 0.05mL.Serum levels of VEGF and IGF-1 were measured by enzyme-linked immunosorbent assay (ELISA) in both groups before and 3 months after treatment.The clinical efficacy and quality of life of the patients were evaluated after 3 months of treatment of the investigation;1 month after treatment of adverse reactions was also recorded.Results The levels of VEGF and IGF-1 were significantly higher than those of in the control group and the observation group before and after drug treatment.The results of comparison between the two groups showed that the serum levels of VEGF in the serum of the control group and the observation group were significantly higher than those in the control group and IGF-1 were significantly lower than those before treatment.Serum levels of VEGF and IGF-1 were significantly lower in the serum of patients after 3 months of treatment compared with 1 month after treatment.At the same time point, the comparison between the observation group and the control group included that one month after treatment and 3 months after treatment.The level of VEGF and IFG-1 in the serum of the observation group was significantly lower than that of the control group.The total effective rate was 95% higher in the observation group than in the control group (79%).After 3 months of treatment, the scores of self-care ability, activity ability, social and psychological ability of the observation group were higher than those of the control group (P<0.05).After 1 month of treatment, the anterior chamber inflammation, Corneal edema and high intraocular pressure were significantly lower than the control group (P<0.05).Conclusion Composin can significantly reduce the levels of VEGF and IGF-1 in patients with diabetic retinopathy, delay the formation of blood vessels, improve the quality of life of patients, and have good clinical efficacy and safety.